PDS Biotechnology Corp financial data

Symbol
PDSB on Nasdaq
Industry
Pharmaceutical Preparations
Location
303 A College Road East, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Edge Therapeutics, Inc. (to 3/18/2019)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 457 % -56.7%
Debt-to-equity 107 % +47.6%
Return On Equity -137 % -18%
Return On Assets -66.1 % +1.67%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.8M shares +19.3%
Common Stock, Shares, Outstanding 36.8M shares +19.1%
Entity Public Float 148M USD +50.8%
Common Stock, Value, Issued 12.1K USD +19.1%
Weighted Average Number of Shares Outstanding, Basic 36.7M shares +19.1%
Weighted Average Number of Shares Outstanding, Diluted 36.7M shares +19.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 25.1M USD -26.8%
General and Administrative Expense 14.6M USD +5.05%
Operating Income (Loss) -39.7M USD +17.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.2M USD +28.9%
Income Tax Expense (Benefit) -869K USD +38.2%
Net Income (Loss) Attributable to Parent -40.7M USD +14.8%
Earnings Per Share, Basic -1.23 USD/shares +23.1%
Earnings Per Share, Diluted -1.23 USD/shares +23.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 57.7M USD -4.77%
Assets, Current 60.2M USD -5.04%
Property, Plant and Equipment, Net 153K USD +6.5%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 60.5M USD -5.11%
Accounts Payable, Current 3.25M USD -26.3%
Accrued Liabilities, Current 1.95M USD -42.3%
Liabilities, Current 15.7M USD +98.3%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 29.6M USD -5.53%
Retained Earnings (Accumulated Deficit) -163M USD -33.1%
Stockholders' Equity Attributable to Parent 30.9M USD -4.7%
Liabilities and Equity 60.5M USD -5.11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.94M USD +24.6%
Net Cash Provided by (Used in) Financing Activities 20M USD +338%
Common Stock, Shares Authorized 150M shares +100%
Common Stock, Shares, Issued 36.8M shares +19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 57.7M USD -4.77%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.17M USD +21.5%
Deferred Tax Assets, Valuation Allowance 56.6M USD +33.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 56.7M USD +33.3%
Operating Lease, Liability 59.7K USD -84.9%
Depreciation 4.74K USD +50.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.7M USD +14.8%
Lessee, Operating Lease, Liability, to be Paid 60.3K USD -85.6%
Property, Plant and Equipment, Gross 267K USD +131%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 683 USD -97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 194M USD +25.2%
Deferred Tax Assets, Net of Valuation Allowance 56.8K USD -61.7%
Share-based Payment Arrangement, Expense 5.2M USD +27.5%
Interest Expense 4.41M USD +93.3%